Remove Generic Drugs Remove Pharma Companies Remove Pharmacy Remove Production
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

California’s budget documents give few details about the tender process, but state that CalRx will spend $50 million to partner with a contract manufacturer to develop biosimilar insulin products in vial and pen form. This CMO will be responsible for product roll-out and distribution. In-house manufacturing the norm.

Insulin 328
article thumbnail

Pharma’s climate change vulnerability and opportunity

pharmaphorum

tons of carbon dioxide equivalent (CO 2 e) for every $1m it generated – placing it above even the automotive industry, which emitted 31.4 tons per $1m generated in the same year, in terms of contributing to global greenhouse gases (GHGs). “As In 2019, the pharmaceutical industry produced 48.55 Vulnerability . Adaptability.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. This looks like it may change shape in the future for the region, if the proposal put forward by the commission is adopted.

article thumbnail

India: Why is the country ramping up drug discovery research?

Drug Discovery World

In the global pharmaceuticals market, India ranks third worldwide for production by volume and the domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 1. To many, the country is referred to as the ‘pharmacy of the world’. To many, the country is referred to as the ‘pharmacy of the world’.